{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001321834","name":"Q/C TECHNOLOGIES, INC.","summary":"TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals) is a clinical-stage pharmaceutical company focused on extending healthy lifespan. It is developing two therapeutic platforms: Isomyosamine, a small molecule immunometabolic regulator targeting autoimmune diseases including sarcopenia, frailty, and rheumatoid arthritis; and Supera-CBD, a synthetic CBD analog targeting epilepsy, pain, and anxiety/depression. The company also holds a 13% stake in Oravax Medical and a 2.5% royalty on Oravax net sales related to a COVID-19 vaccine candidate.","people":[],"products":[{"name":"Isomyosamine","type":"platform","description":"Clinical-stage small molecule immunometabolic regulator targeting autoimmune diseases including sarcopenia, frailty, rheumatoid arthritis, and inflammatory bowel disease by inhibiting pro-inflammatory cytokines such as TNF-alpha."},{"name":"Supera-CBD","type":"platform","description":"Synthetic analog of CBD being developed to treat epilepsy, pain, and anxiety/depression via CB2 receptor, opioid receptors, and MAO type B."}],"partnerships":[{"partner_name":"Charles River Laboratories","partnership_type":"development","description":"Conducted a 13-week EEG safety study of Isomyosamine (MYMD-1) in beagle dogs; results completed December 2024 and favorably received by FDA.","start_date":null},{"partner_name":"Premas Biotech PVT Ltd.","partnership_type":"licensing","description":"Previously licensed COVID-19 vaccine platform to Cystron Biotech; rights contributed to Oravax Medical in April 2021.","start_date":null},{"partner_name":"Oravax Medical, Inc.","partnership_type":"strategic","description":"Received 13% equity stake and 2.5% royalty on net sales after contributing COVID-19 vaccine assets via Cystron Biotech.","start_date":null},{"partner_name":"SRQ Patent Holdings","partnership_type":"licensing","description":"Assigned Isomyosamine patent rights to the Company in November 2016 in exchange for a royalty on product sales and other revenue.","start_date":null},{"partner_name":"SRQ Patent Holdings II, LLC","partnership_type":"licensing","description":"Granted a royalty on product sales from Supera-CBD intellectual property as partial consideration for assignment from Supera Pharmaceuticals.","start_date":null}],"affiliations":[],"origin":{"leaf":"96a31e3f3f1199a13714132dd34c2c353e5b2cd80e0a469d326def9aa727b426","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"3a0a50279cdae3d17da0101327f7d06aaeb7fa56850a90df4a27e4e0e764f5c7","parent":"d7bf00cccee67a4c12004146ea792c496b40537949fa8e8502966e561361edb1","source":"0001641172-25-003814","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":165,"hourly_limit":500,"remaining":335,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}